NASDAQ:ASPX - Auspex Pharmaceuticals Stock Price, Price Target & More

$100.96 0.00 (0.00 %)
(As of 04/22/2018 06:36 AM ET)
Previous Close$100.96
Today's RangeN/A
52-Week Range$14.75 - $101.00
VolumeN/A
Average Volume1.02 million shs
Market Capitalization$3.21 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Auspex Pharmaceuticals (NASDAQ:ASPX)

Auspex Pharmaceuticals logoAuspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.

Receive ASPX News and Ratings via Email

Sign-up to receive the latest news and ratings for ASPX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ASPX
CUSIPN/A
WebN/A
Phone+1-858-5582400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-61.66%
Return on Assets-50.55%

Miscellaneous

EmployeesN/A
Outstanding Shares31,820,000

How to Become a New Pot Stock Millionaire

Auspex Pharmaceuticals (NASDAQ:ASPX) Frequently Asked Questions

What is Auspex Pharmaceuticals' stock symbol?

Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."

How were Auspex Pharmaceuticals' earnings last quarter?

Auspex Pharmaceuticals Inc (NASDAQ:ASPX) released its earnings results on Monday, March, 16th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.

Who are some of Auspex Pharmaceuticals' key competitors?

Has Auspex Pharmaceuticals been receiving favorable news coverage?

Headlines about ASPX stock have trended positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Auspex Pharmaceuticals earned a media sentiment score of 0.44 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Auspex Pharmaceuticals?

Shares of ASPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auspex Pharmaceuticals' stock price today?

One share of ASPX stock can currently be purchased for approximately $100.96.

How big of a company is Auspex Pharmaceuticals?

Auspex Pharmaceuticals has a market capitalization of $3.21 billion.

How can I contact Auspex Pharmaceuticals?

Auspex Pharmaceuticals' mailing address is 3333 N Torrey Pines Ct Ste 400, LA JOLLA, CA 92037-1023, United States. The biopharmaceutical company can be reached via phone at +1-858-5582400.


MarketBeat Community Rating for Auspex Pharmaceuticals (ASPX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Auspex Pharmaceuticals and other stocks. Vote "Outperform" if you believe ASPX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASPX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Auspex Pharmaceuticals (NASDAQ:ASPX) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/22/2016 forward)

Earnings

Auspex Pharmaceuticals (NASDAQ:ASPX) Earnings History and Estimates Chart

Earnings by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)

Auspex Pharmaceuticals (NASDAQ ASPX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015Q4 2014($0.59)($0.74)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.45)($0.73)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.40)($0.45)ViewN/AView Earnings Details
5/13/2014Q114($0.47)($0.52)ViewN/AView Earnings Details
3/27/2014Q4 2013($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Auspex Pharmaceuticals (NASDAQ:ASPX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Auspex Pharmaceuticals (NASDAQ ASPX) Insider Trading and Institutional Ownership History

Insider Trading History for Auspex Pharmaceuticals (NASDAQ:ASPX)

Auspex Pharmaceuticals (NASDAQ ASPX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/16/2015David A StamlerInsiderSell3,000$80.00$240,000.00View SEC Filing  
2/13/2015Ventures Vii Lp CmeaMajor ShareholderSell122,667$63.08$7,737,834.36View SEC Filing  
2/11/2015Ventures Vii Lp CmeaMajor ShareholderSell84,154$61.06$5,138,443.24View SEC Filing  
2/6/2015Ventures Vii Lp CmeaMajor ShareholderSell93,179$59.39$5,533,900.81View SEC Filing  
1/28/2015Alex ZissonDirectorSell730,000$53.11$38,770,300.00View SEC Filing  
1/28/2015James E FlynnInsiderBuy1,500,000$56.50$84,750,000.00View SEC Filing  
1/28/2015Panorama Capital, L.P.Major ShareholderSell270,000$53.11$14,339,700.00View SEC Filing  
12/22/2014David A StamlerInsiderSell2,660$53.55$142,443.00View SEC Filing  
12/18/2014Ventures Vii Lp CmeaMajor ShareholderSell195,000$50.14$9,777,300.00View SEC Filing  
10/30/2014Ventures Vii Lp CmeaMajor ShareholderSell19,000$27.15$515,850.00View SEC Filing  
10/28/2014Ventures Vii Lp CmeaMajor ShareholderSell14,500$27.02$391,790.00View SEC Filing  
10/27/2014Ventures Vii Lp CmeaMajor ShareholderSell3,413$27.11$92,526.43View SEC Filing  
10/24/2014Ventures Vii Lp CmeaMajor ShareholderSell16,500$26.97$445,005.00View SEC Filing  
10/6/2014Ventures Vii Lp CmeaMajor ShareholderSell7,109$23.45$166,706.05View SEC Filing  
9/19/2014Gerald T ProehlDirectorBuy1,466$21.75$31,885.50View SEC Filing  
9/5/2014Ventures Vii Lp CmeaMajor ShareholderSell25,600$23.86$610,816.00View SEC Filing  
9/3/2014Ventures Vii Lp CmeaMajor ShareholderSell22,700$23.08$523,916.00View SEC Filing  
8/28/2014Ventures Vii Lp CmeaMajor ShareholderSell29,600$22.03$652,088.00View SEC Filing  
8/26/2014Ventures Vii Lp CmeaMajor ShareholderSell6,300$21.35$134,505.00View SEC Filing  
8/22/2014Ventures Vii Lp CmeaMajor ShareholderSell1,700$20.56$34,952.00View SEC Filing  
7/16/2014R Scott GreerDirectorBuy5,190$19.25$99,907.50View SEC Filing  
2/10/2014James E FlynnInsiderBuy700,000$12.00$8,400,000.00View SEC Filing  
2/10/2014Panorama Capital, L.P.Major ShareholderBuy333,334$12.00$4,000,008.00View SEC Filing  
2/10/2014Pratik ShahCEOBuy8,333$12.00$99,996.00View SEC Filing  
2/10/2014Sepehr SarsharDirectorBuy67,263$12.00$807,156.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Auspex Pharmaceuticals (NASDAQ ASPX) News Headlines

Source:
DateHeadline
LONDON MARKET EARLY CALL: Higher Call After US Jobs Boost SentimentLONDON MARKET EARLY CALL: Higher Call After US Jobs Boost Sentiment
www.morningstar.co.uk - March 12 at 9:00 AM
Auspex Pharmaceuticals (ASPX) versus Its Peers Head-To-Head AnalysisAuspex Pharmaceuticals (ASPX) versus Its Peers Head-To-Head Analysis
www.americanbankingnews.com - January 29 at 5:14 PM
Reviewing Auspex Pharmaceuticals (ASPX) & The CompetitionReviewing Auspex Pharmaceuticals (ASPX) & The Competition
www.americanbankingnews.com - January 13 at 3:06 PM
Head-To-Head Comparison: Auspex Pharmaceuticals (ASPX) and Its PeersHead-To-Head Comparison: Auspex Pharmaceuticals (ASPX) and Its Peers
www.americanbankingnews.com - January 8 at 1:40 PM
Comparing Auspex Pharmaceuticals (ASPX) and The CompetitionComparing Auspex Pharmaceuticals (ASPX) and The Competition
www.americanbankingnews.com - December 31 at 11:28 AM
Citron Research On AveXis: This Will Be One Of 2017s Biotech BlowupsCitron Research On AveXis: This Will Be One Of 2017's Biotech Blowups
finance.yahoo.com - November 28 at 5:28 AM
Avexis Inc. (AVXS): RA Capital Management Ups Its StakeAvexis Inc. (AVXS): RA Capital Management Ups Its Stake
finance.yahoo.com - November 28 at 5:28 AM
Chardan Analyst Suggests An AveXis-Ionis Pair TradeChardan Analyst Suggests An AveXis-Ionis Pair Trade
finance.yahoo.com - October 5 at 1:54 PM
Sanofi Genzyme Reports Results From Phase 2 Open-Label Extension StudySanofi Genzyme Reports Results From Phase 2 Open-Label Extension Study
www.rttnews.com - July 10 at 4:07 PM
Hurry! These 5 Stocks Are About to Break Out ExplosivelyHurry! These 5 Stocks Are About to Break Out Explosively
www.thestreet.com - January 13 at 4:10 PM
Pharma, Biotech Shares Down After Trump Pledge To Cut Drug PricesPharma, Biotech Shares Down After Trump Pledge To Cut Drug Prices
www.morningstar.co.uk - December 8 at 3:55 PM
All Eyes on These Two Biotech Firms Ahead of FDA Decisions (VCEL, SGYP)All Eyes on These Two Biotech Firms Ahead of FDA Decisions (VCEL, SGYP)
www.investopedia.com - December 8 at 3:55 PM
Heres Why AveXis Shot Up 24.5% TodayHere's Why AveXis Shot Up 24.5% Today
www.fool.com - November 2 at 3:58 PM
If you want to know which way the market is heading, follow the leadersIf you want to know which way the market is heading, follow the leaders
www.marketwatch.com - October 17 at 3:35 PM
AUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquisAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquis
biz.yahoo.com - May 5 at 4:50 PM
AUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsAUSPEX PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - April 17 at 9:02 AM

SEC Filings

Auspex Pharmaceuticals (NASDAQ:ASPX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Auspex Pharmaceuticals (NASDAQ:ASPX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Auspex Pharmaceuticals (NASDAQ ASPX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.